| Literature DB >> 35280797 |
Nicola Onorini1, Pietro Spennato1, Valentina Orlando1,2, Fabio Savoia3, Camilla Calì3, Carmela Russo4, Lucia De Martino5, Maria Serena de Santi1, Giuseppe Mirone1, Claudio Ruggiero1, Lucia Quaglietta5, Giuseppe Cinalli1.
Abstract
Objective: A single-institution cohort of 92 consecutive pediatric patients harboring tumors involving the fourth ventricle, surgically treated via the telovelar or transvermian approach, was retrospectively reviewed in order to analyze the impact of surgical route on surgery-related outcomes and cumulative survival.Entities:
Keywords: cerebellar mutism; children; fourth ventricle; telovelar; transvermian
Year: 2022 PMID: 35280797 PMCID: PMC8912940 DOI: 10.3389/fonc.2022.821738
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Anatomical classification of posterior fossa tumors requiring surgical access to the fourth ventricle. (A) Mainly/purely intraventricular, without evident brainstem infiltration or extensive vermian infiltration. (B) Midbrain/intra-aqueductal tumor with significant bulging in the upper part of the fourth ventricle. (C) Cerebellar/vermian tumor with extensive parenchymal/vermian infiltration and secondary bulging into the fourth ventricle. (D) Cerebellopontine angle tumors extending into the fourth ventricle through the Luschka foramen/foramina. (E) Brainstem tumors with dorsally exophytic fourth ventricular component. (F) Giant tumors with extensive posterior fossa involvement, including a significant fourth ventricle component..
Preoperative clinical, radiological, and pathological assessment.
| Total No. (%) | Telovelar No. (%) | Transvermian No. (%) | ||
|---|---|---|---|---|
|
| <6 months | 7 (7) | 6 (86) | 1 (14) |
| 6 months–5 years | 21 (23) | 14 (67) | 7 (33) | |
| >5 years | 64 (70) | 31 (48) | 33 (52) | |
|
| 3 (3) | 3 | 0 | |
|
| ICH | 81 (91) | 43 (53) | 38 (47) |
| Cerebellar syndrome | 34 (38) | 15 (47) | 18 (53) | |
| CN palsy | 29 (33) | 16 (55) | 13 (45) | |
| Various2 | 36 (39) | 19 (52) | 17 (48) | |
|
| Fourth ventricle (pure) | 23 (25) | 14 (61) | 9 (39) |
| + Mes./Aq. | 4 (4) | 4 | 0 | |
| + Verm./Cerebell. | 48 (53) | 16 (33) | 32 (67) | |
| + CPA | 4 (4) | 4 | 0 | |
| + BS dorsally exophytic | 12 (13) | 11 (92) | 1 (8) | |
| + Entire PCF | 1 (1) | 1 | 0 | |
|
| No | 39 (42) | 18 (46) | 21 (54) |
| Unilateral | 34 (37) | 21 (62) | 13 (38) | |
| Bilateral | 19 (21) | 12 (63) | 7 (37) | |
|
| No | 23 (25) | 12 (52) | 11 (48) |
| Magendie | 37 (40) | 15 (42) | 22 (58) | |
| + Cisterna magna | 20 (22) | 15 (75) | 5 (25) | |
| + Cervical spinal canal | 12(13) | 9 (75) | 3 (25) | |
|
| No | 52 (57) | 25 (48) | 27 (52) |
| BS infiltration | 28 (30) | 15 (54) | 13 (46) | |
| BS dorsally exophytic | 12 (13) | 11 (92) | 1 (8) | |
|
| No | 22 (24) | 15 (68) | 7 (32) |
| Yes | 70 (76) | 36 (51) | 34 (49) | |
|
| <15 cm3 | 28 (33) | 20 (71) | 8 (29) |
| 15–26 cm3 | 30 (34) | 15 (50) | 15 (50) | |
| >26 cm3 | 28 (33) | 14 (50) | 14 (50) | |
|
| Medulloblastoma | 37 (40) | 16 (43) | 21 (57) |
| Pilocytic astrocytoma | 28 (30) | 13 (46) | 15 (54) | |
| Ependymoma | 7 (8) | 4 (57) | 3 (43) | |
| Anaplastic ependymoma | 6 (7) | 5 (83) | 1 (17) | |
| ATRT | 6 (7) | 5 (83) | 1 (17) | |
| Various | 8 (8) | 8 (8) | 0 | |
|
| NF-1 | 4 (4) | 2 (50) | 2 (50) |
| Turcot syndrome | 1 (1) | 0 | 1 | |
|
| ALC-RET | 1 (1) | 1 | 0 |
| AUTS2 | 1 (1) | 0 | 1 |
CN, cranial nerve; Mes., mesencephalic; Aq., aqueductal; Ver., vermian; Cerebell, cerebellar; CPA, cerebellopontine angle; BS, brainstem; ICH, intracranial hypertension; PCF, posterior cranial fossa; CE, contrast enhancement; ATRT, atypical teratoid/rhabdoid tumor; NF-1, neurofibromatosis type 1; ALC-RET, ALC-RET gene mutation; AUTS2, AUTS2 gene mutation.
1Most patients presented with more than one sign/symptom.
2Various: torticollis, evolutive macrocrania, diffuse hypotonia, opisthotonic posturing, irritability.
3We used two tertiles to split volumetric data into three groups. N = 86 computable MRI sequences for volumetric analysis.
4According to the 2016 WHO Classification of Tumors of the Central Nervous System.
Surgery and postoperative clinical/radiological assessment.
| Total No. (%) | Missing data | Telovelar No. (%) | Transvermian No. (%) | |
|---|---|---|---|---|
|
| 80 (88) | n = 1 | 51 (64) | 29 (36) |
|
| 3 (3) | n = 1 | 3 | 0 |
|
| 13 (16) | n = 11 | 11 (85) | 2 (15) |
|
| 38 (43) | n = 1 | 26 (68) | 12 (32) |
|
| 48 (53) | n = 1 | 15 (31) | 33 (69) |
| | 48 (53) | n = 1 | 26 (54) | 22 (46) |
| Cerebellar syndrome | 25 (28) | 16 (64) | 9 (36) | |
| Upper CN palsy | 23 (26) | 14 (61) | 9 (39) | |
| Pyramidal syndrome | 14 (16) | 8 (57) | 6 (43) | |
| Cerebellar mutism | 10 (11) | 4 (40) | 6 (60) | |
| Dysphagia | 7 (8) | 4 (57) | 3 (43) | |
| Dysphonia | 3 (3) | 3 | 0 | |
|
| 25 (31) | n = 112 | 16 (64) | 9 (36) |
| CN palsy | 16 (20) | 10 (63) | 6 (47) | |
| Cerebellar syndrome | 14 (18) | 7 (50) | 7 (50) | |
| Pyramidal syndrome | 9 (11) | 5 (56) | 4 (44) | |
| Dysphagia | 2 (3) | 1 (50) | 1 (50 | |
|
| n = 1 | |||
| <48 h | 80 (88) | 41 (51) | 39 (49) | |
| >48 h | 11 (12) | 8 (73) | 3 (27) | |
|
| 19 (21) | 14 (74) | 5 (26) | |
| | ||||
| Pseudomeningocele | 21 (23) | 9 (43) | 12 (57) | |
| CSF leak | 7 (8) | 4 (57) | 3 (43) | |
| CSF infections <1 month | 4 (4) | 2 (50) | 2 (50) | |
| CSF infections >1 month | 1 (1) | 0 | 1 (50) | |
|
| n = 2 | |||
| No residual disease | 57 (63) | 28 (49) | 29 (51) | |
| <1.5 cm3 | 23 (26) | 15 (65) | 8 (35) | |
| >1.5 cm3 | 10 (11) | 6 (60) | 4 (40) | |
|
| n = 2 | |||
| Total | 57 (63) | 29 (51) | 28 (49) | |
| Subtotal (>90%) | 21 (24) | 13 (62) | 8 (38) | |
| Partial (<90%) | 12 (13) | 8 (67) | 4 (43) | |
|
| 33 | n = 2 | ||
| Brainstem/floor of the fourth ventricle | 18 (55) | 12 (67) | 6 (33) | |
| Fastigium/CV | 10 (30) | 6 (60) | 4 (40) | |
| Various | 8 (42) | 4 (50) | 4 (50) | |
|
| 18 (20) | |||
| Intraventricular blood clots | 8 (9) | 2 (25) | 6 (75) | |
| Pericerebellar fluid collections | 6 (7) | 2 (33) | 4 (67) | |
| Ischemia (PICA territory) | 1 (1) | 1 | 0 | |
| Epidural hematoma | 1 (1) | 0 | 1 | |
| Cerebellar swelling | 1 (1) | 1 | 0 | |
|
| 65 (93) | |||
| ETV | 43 (66) | 22 (51) | 21 (49) | |
| EVD | 13 (20) | 5 (38) | 8 (62) | |
| VPS | 9 (14) | 8(89) | 1 (11) | |
|
| 29 (74) | n = 4 | 14 (48) | 15 (52) |
|
| 10 (26) | n = 4 | 6 (60) | 4 (40) |
|
| ||||
| Preop. CSF-diversion procedures | 14 (224) | 9 (64) | 5 (36) | |
| No preop. CSF-diversion procedures | 2 (404) | 0 | 2 | |
| No hydrocephalus at onset | 7 (324) | 5 (71) | 2 (29) | |
|
| 23 (25) | 17 (74) | 6 (26) |
CVP, cardiovascular parameters; CT, computed tomography; BS, brainstem; CV, cerebellar vermis; CN, cranial nerve; CSF, cerebrospinal fluid; EOR, extension of resection; ETV, endoscopic third ventriculostomy; EVD, external ventricular drainage; VPS, ventriculo-peritoneal shunt; preop., preoperative.
1Most patients presented with more than one sign/symptom.
2n = 11 patients died before 1 year of follow-up.
3n = 3 cases of multiple location.
4n = 65 (93%) of n = 70 patients with hydrocephalus at onset were treated with CSF-diversion procedures; n = 5 (7%) patients with hydrocephalus were referred directly to surgery; in n = 22 cases, preoperative hydrocephalus was not detected (see ).
Surgical approach and postoperative outcomes.
| Transient deficit | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Univariate analysis | Multivariate analysis* | |||||||||
| n | % | n | % | OR | 95% CI | p | OR | 95% CI | p | |||
|
| 26 | 52 | 24 | 48 | ||||||||
|
| 22 | 54 | 19 | 45 | 1.07 | 0.47–2.44 | 0.88 | 1.28 | 0.39–4.15 | 0.68 | ||
|
| ||||||||||||
|
|
| |||||||||||
|
| 16 | 36 | 28 | 64 | ||||||||
|
| 9 | 24 | 28 | 76 | 0.56 | 0.21–1.48 | 0.25 | 0.86 | 0.21–3.43 | 0.83 | ||
|
| ||||||||||||
|
|
| |||||||||||
|
| 8 | 16 | 41 | 84 | ||||||||
|
| 3 | 7 | 39 | 93 | 0.39 | 0.10–1.59 | 0.19 | 1.26 | 0.17–9.61 | 0.82 | ||
|
| ||||||||||||
|
|
| |||||||||||
|
| 4 | 8 | 46 | 92 | ||||||||
|
| 6 | 15 | 35 | 85 | 1.97 | 0.52–7.51 | 0.32 | 0.81 | 0.16–4.12 | 0.81 | ||
|
| ||||||||||||
|
|
| |||||||||||
|
| 14 | 28 | 36 | 72 | ||||||||
|
| 5 | 12 | 37 | 88 | 0.35 | 0.11–1.06 | 0.06 | 0.26 | 0.06–1.23 | 0.09 | ||
|
| ||||||||||||
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| 28 | 57 | 15 | 31 | 6 | 12 | ||||||
|
| 29 | 71 | 8 | 19 | 4 | 10 | 0,58 | 0.24–1.37 | 0.21 | 0.44 | 0.12–1.60 | 0.22 |
*Penalized maximum likelihood estimation.
**Ordered logistic model.
Figure 2Kaplan–Meier survival estimates. CS, cumulative survival; CI, confidence interval; y, year. (A) Kaplan–Meier survival estimates (histological grading): 1- and 3-year CS are analyzed in relation to histological grading (WHO 1–2 vs. WHO 3–4), showing a better 1- and 3-year CS for low-grade group (log-rank test, p = 0.0001). Low-grade tumors: 1-year CS, 97.6% (95% CI: 83.9%–99.7%); 3-year CS, 97.6% (95% CI: 83.9%–99.7%). High-grade tumors: 1-year CS, 82% (95% CI: 68.2%–90.2%); 3-year CS: 62% (95% CI: 46.4%–74.2%). (B) Kaplan-Meier survival estimates (histology): 1- and 3-year CS are analyzed in relation to histology (log-rank test, p = 0.03). Pilocytic astrocytoma: 1- and 3-year CS, 100%. Non-anaplastic ependymomas: 1-y CS, 85.7% (95% CI: 33.4%–97.9%); 3-year CS, 85.7% (95% CI, 33.4%–97.9%). Medulloblastomas: 1-year CS, 91.9% (95% CI, 76.9%–97.3%); 3-year CS, 73.6% (95% CI: 55.1%–85.4%). Anaplastic ependymomas: 1-year CS, 100%; 3-year CS, 66.7% (95% CI: 19.5%–90.4%). (C) Kaplan–Meier survival estimates (surgical approach for high-grade tumors): Considering the choice of surgical approach for high-grade tumors (WHO 3–4), we found better 1- and 3-years CS of transvermian approach when compared to telovelar approach with statistical significance (log-rank test, p = 0.048). Telovelar approach: 1-year CS, 76.9% (95% CI: 55.7%–88,9%); 3-year CS, 48.8% (95% CI, 28.5%–66.4%). Transvermian approach: 1-year CS, 87.5% (95% CI: 66.1%–95.8%); 3-year CS, 78% (95% CI, 54.8%–90.3%). The power of predicting factors (surgical approach for high-grade tumors and residual tumor volume) is evaluated in a Cox proportional hazard model ( ).
Cox regression (High-grade tumors).
|
|
|
|
| |
|---|---|---|---|---|
| Surgery | 0.47 | −1.39 | 0.165 | 0.16–1.37 |
| Residual volume (cm3) | 2.53 | 2.99 | 0.003 | 1.38–4.64 |
HR, hazard ratio; CI, confidence interval; p, p-value.
Surgery of fourth ventricle tumors: published pediatric case series.
| Authors, year | No of patients | Telovelar approach (%) | Transvermian approach (%) | CMS (%) | GTR (%) |
|---|---|---|---|---|---|
| Kellogg & Piatt, 1997 ( | 11 | 100 | 0 | 0 | 81.2 |
| Rajesh et al., 2007 ( | 15 | 100 | 0 | 13.3 | 93.3 |
| Zaheer& Wood, 2010 ( | 20 | 100 | 0 | 30 | 70 |
| Qiu et al., 2016 ( | 26 | 100 | 0 | 7.7 | 84.6 |
| Eissa, 2018 ( | 40 | 100 | 0 | 2.5 | 45 |
| Atallah et al., 2019 ( | 44 | 100 | 0 | 13.6 | 84.1 |
| Cobourn et al., 2020 ( | 63 | * | 53.8 | 10.8 | NR |
| Toescu et al., 2020 ( | 167 | 33.0 | 64.1 | 28.7 | 70.7 |
|
|
|
|
|
|
|
CMS, cerebellar mutism syndrome; GTR, gross total removal; NR, not reported.
*Frequency of telovelar approach: not reported.